JCI Insight (Jan 2021)

Islet cell dedifferentiation is a pathologic mechanism of long-standing progression of type 2 diabetes

  • Kikuko Amo-Shiinoki,
  • Katsuya Tanabe,
  • Yoshinobu Hoshii,
  • Hiroto Matsui,
  • Risa Harano,
  • Tatsuya Fukuda,
  • Takato Takeuchi,
  • Ryotaro Bouchi,
  • Tokiyo Takagi,
  • Masayuki Hatanaka,
  • Komei Takeda,
  • Shigeru Okuya,
  • Wataru Nishimura,
  • Atsushi Kudo,
  • Shinji Tanaka,
  • Minoru Tanabe,
  • Takumi Akashi,
  • Tetsuya Yamada,
  • Yoshihiro Ogawa,
  • Eiji Ikeda,
  • Hiroaki Nagano,
  • Yukio Tanizawa

Journal volume & issue
Vol. 6, no. 1

Abstract

Read online

Dedifferentiation has been implicated in β cell dysfunction and loss in rodent diabetes. However, the pathophysiological significance in humans remains unclear. To elucidate this, we analyzed surgically resected pancreatic tissues of 26 Japanese subjects with diabetes and 11 nondiabetic subjects, who had been overweight during adulthood but had no family history of diabetes. The diabetic subjects were subclassified into 3 disease stage categories, early, advanced, and intermediate. Despite no numerical changes in endocrine cells immunoreactive for chromogranin A (ChgA), diabetic islets showed profound β cell loss, with an increase in α cells without an increase in insulin and glucagon double-positive cells. The proportion of dedifferentiated cells that retain ChgA immunoreactivity without 4 major islet hormones was strikingly increased in diabetic islets and rose substantially during disease progression. The increased dedifferentiated cell ratio was inversely correlated with declining C-peptide index. Moreover, a subset of islet cells converted into exocrine-like cells during disease progression. These results indicate that islet remodeling with dedifferentiation is the underlying cause of β cell failure during the course of diabetes progression in humans.

Keywords